Quality of life in patients with cancer treatment related nausea and vomiting – a scoping review
Authors:
- Rachel LeongRLRachel Leong
- Emily MacMillanEMEmily MacMillan
- Christina YangCYChristina Yang
- Japyjot SinghJSJapyjot Singh
- Jefferson ChanJCJefferson Chan
- Carlo DeAngelisCDCarlo DeAngelis
- Tarek HijalTHTarek Hijal
- Terry NgTNTerry Ng
- Kristopher DennisKDKristopher Dennis
- Vassilios VassiliouVVVassilios Vassiliou
- Olivera GojsevicOGOlivera Gojsevic
- 19 October 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Current Opinion in Supportive & Palliative Care
- Vol. 20 (4) , 272-286
Abstract
Purpose: Treatment-related nausea and vomiting (TRNV) is among the most distressing and commonly reported adverse effects of antineoplastic therapy and can significantly impair patients’ quality of life (QoL). This review summarizes the evidence on how TRNV affects QoL across cancer types, treatment regimens, antiemetic strategies, and phases of TRNV. Recent findings: TRNV negatively affects all domains of QoL in patients with cancer, particularly physical and functional well-being. Studies consistently reported worsened fatigue, insomnia, appetite loss, pain, impaired activities of daily living, meal enjoyment, and role functioning. Psycho-social and cognitive effects were also observed, although findings were more variable. Despite advances in antiemetic interventions and supportive strategies, patients continued to experience a substantial symptom burden and worsened QoL following treatment. Most studies explored chemotherapy-related TRNV and did not focus on a specific cancer type. A wide range of QoL instruments were used, but no single tool comprehensively assessed all QoL domains while remaining specific to cancer-related nausea and vomiting. Summary: TRNV is associated with a significant decline in QoL among patients with cancer. Further research on QoL after TRNV within specific cancer types and treatment modalities and the development of a more comprehensive QoL tool are needed to improve cross-study comparability and to better understand patient outcomes.Keywords
This publication has 32 references indexed in Scilit:
- Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomitingEuropean Journal of Cancer, 2025
- Effect of a Standardized Ginger Root Powder Regimen on Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Double-Blind, Placebo-Controlled Randomized TrialJournal of the Academy of Nutrition and Dietetics, 2023
- Quality of Life Associated with Nausea and Vomiting from Anthracycline-Based Chemotherapy: A Pooled Data Analysis from Three Prospective TrialsThe Oncologist, 2021
- Radiation induced nausea and vomitingEuropean Journal of Pharmacology, 2014
- Management of Chemotherapy-Induced Nausea and VomitingDrugs, 2013
- Symptom Prevalence and Management of Cancer Patients in LebanonJournal of Pain and Symptom Management, 2012
- Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in KoreaQuality of Life Research, 2011
- Validation and Psychometric Assessment of a Short Clinical Scale to Measure Chemotherapy-Induced Nausea and Vomiting: The MASCC Antiemesis ToolJournal of Pain and Symptom Management, 2007
- The development of the EORTC QLQ-C15-PAL: A shortened questionnaire for cancer patients in palliative careEuropean Journal of Cancer, 2006
- Coping, Distress, and Survival Among Patients With Lung CancerArchives of General Psychiatry, 1999